Plexus Corp. is a global provider of electronic manufacturing services (EMS) and design-to-manufacturing solutions, headquartered in Neenah, Wisconsin. The company partners with customers to design, build, and service highly complex products across three market sectors: Aerospace/Defense, Healthcare/Life Sciences, and Industrial. Plexus specializes in products that operate in demanding regulatory environments, combining engineering, supply chain, manufacturing, and aftermarket services.
In fiscal 2026, Plexus generated record revenue of approximately $4.97 billion, up 23% year over year, and reported a market capitalization near $6.1 billion. Its top 10 customers accounted for 56% of fourth-quarter revenue, reflecting deep relationships with a concentrated base of large original equipment manufacturers. Investors follow the stock for its exposure to defense, medical technology, and semiconductor capital equipment end markets, as well as management's stated goal of steadily expanding operating margins. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, PLXS shares declined approximately 18%, moving from a closing price near $266 to a recent level around $218. The move was uneven: the stock climbed into early October before a sharp sell-off in the second half of the month, including a notable single-day decline in late October.
Over the last quarter, the stock is down roughly 9%. The three-month trend has been volatile rather than linear. After trading near $240–$250 at the end of July, the shares rallied through September and into early October, then gave back those gains as selling accelerated. The result is a net quarterly decline that is smaller than the 30-day drop, underscoring how much of the weakness was concentrated in recent weeks.
The decline stands out because it coincided with strong fundamentals. On October 28, Plexus reported fiscal fourth-quarter revenue of $1.43 billion, up 35% year over year and ahead of guidance, with non-GAAP diluted EPS of $2.84 versus a consensus near $2.55. The company also issued fiscal first-quarter 2027 guidance above analyst expectations. Despite the beat, the shares did not rally and subsequently moved lower, a pattern consistent with a "sell the news" response.
The most likely explanation is profit-taking after a substantial run-up. Having risen more than 70% over the trailing 12 months, the stock entered October at elevated levels, leaving it vulnerable to a valuation reset even in the absence of negative company-specific news. The late-October selling appears tied to that positioning rather than any deterioration in demand or execution, given that fiscal 2026 results, the record $4.9 billion qualified manufacturing funnel, and raised margin targets all pointed in a positive direction.
The broader three-month narrative is one of strong operating momentum punctuated by a sharp pullback. During the quarter, Plexus delivered record fiscal 2026 results, including 23% revenue growth, a 62-day cash cycle, and a return on invested capital of 15.8% — above its 15% goal. Aerospace/Defense revenue grew 23% for the year, Industrial grew 27% (led by semiconductor capital equipment), and Healthcare/Life Sciences grew 19%.
Management's decision to raise its non-GAAP operating margin target to 6.5%–7.0%, up from 6.0%, and to guide fiscal 2027 revenue growth in the mid-to-upper teens reinforced the long-term growth story. Against that backdrop, the stock's late-quarter decline appears driven more by positioning and valuation than by a change in the company's trajectory, leaving the shares down roughly 9% over three months despite improving fundamentals. From what I see, this setup warrants close monitoring in the coming weeks.
Looking ahead, investors are likely to focus on execution against management's fiscal 2027 guidance of mid-to-upper-teens revenue growth and the new 6.5%–7.0% operating margin target. First-quarter commentary points to sequential strength in Aerospace/Defense and Healthcare/Life Sciences, partly offset by demand normalization in the Industrial sector, where semiconductor capital equipment momentum remains a key variable.
Additional factors to monitor include conversion of the record $4.9 billion qualified manufacturing funnel into revenue, the pace of new program ramps, and continued progress on the 62-day cash cycle. Broader risks include semiconductor cycle fluctuations, interest-rate sensitivity across capital equipment end markets, and supply chain or regulatory developments in defense and healthcare. Share repurchases under the newly approved $100 million program may also influence trading dynamics.
In my view, incorporating data-driven resources helps put these moves into context. I often turn to Tickeron’s AI tools when reviewing names like this one to cross-check trends and signals. One approach I find useful is looking at the curated selection of AI trading strategies to see how different models are positioned around current market conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
On October 28, 2026, the Stochastic Oscillator for PLXS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 53 instances where the indicator left the oversold zone. In 42 of the 53 cases the stock moved higher in the following days. This puts the odds of a move higher at over 79%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PLXS's RSI Indicator exited the oversold zone, 12 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where PLXS advanced for three days, in 238 of 332 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
PLXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 184 of 257 cases where PLXS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 72%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PLXS as a result. In 57 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for PLXS turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 25 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
PLXS moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PLXS crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PLXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 69, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. PLXS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.173) is normal, around the industry mean (4.692). P/E Ratio (34.587) is within average values for comparable stocks, (6.176). Projected Growth (PEG Ratio) (0.760) is also within normal values, averaging (1.658). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (1.443) is also within normal values, averaging (4.796).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of electronic manufacturing services
Industry ElectronicComponents